Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors.
Protocol Number:
J1264
Phase:
Phase I
Physician:
Julie Brahmer
Purpose:
This research is being to determine the dose of the investigational drug MEDI4736 that is safe and tolerable in people with advanced solid tumors. MEDI4736 is an antibody that is made in the laboratory. An antibody is a natural protein made by our immune system that binds to other proteins and molecules to fight infection and its ill effects. MEDI4736 binds to another protein in the body and may prevent cancer growth by helping certain blood cells of the immune system eliminate the tumor. This is the first time MEDI4736 will be given to people. Thus, the effects of the drug, good and bad, and the correct dose of the drug to give are unknown. This study will also evaluate: how much MEDI4736 is in the blood at various times, whether the immune system becomes activated following use of MEDI4736 or the body produces antibodies,(proteins produced by the immune system) against MEDI4736, and the effect MEDI4736 has on cancer.
Eligibility:
Treatment:
Population:
Adult
Last Update
04/16/2014 04:02 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer